LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

34%

66%

101 / 374 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. dets 2025, 23:54 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22. dets 2025, 19:08 UTC

Omandamised, ülevõtmised, äriostud

Correction to Alphabet to Buy Intersect Article

22. dets 2025, 17:21 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22. dets 2025, 16:46 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75 Billion in Cash

22. dets 2025, 23:50 UTC

Market Talk

Nikkei May Decline as Yen Rebounds -- Market Talk

22. dets 2025, 23:42 UTC

Market Talk

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22. dets 2025, 22:31 UTC

Tulu

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22. dets 2025, 22:31 UTC

Tulu

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22. dets 2025, 22:30 UTC

Tulu

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

22. dets 2025, 21:37 UTC

Omandamised, ülevõtmised, äriostud

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22. dets 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Capricorn to Acquire Prospective Package From Tempest Minerals

22. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22. dets 2025, 20:54 UTC

Omandamised, ülevõtmised, äriostud

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22. dets 2025, 20:52 UTC

Omandamised, ülevõtmised, äriostud

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22. dets 2025, 20:09 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22. dets 2025, 19:56 UTC

Market Talk

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22. dets 2025, 19:49 UTC

Omandamised, ülevõtmised, äriostud

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22. dets 2025, 19:23 UTC

Market Talk

Mexico's Inflation Seen Easing in Early December -- Market Talk

22. dets 2025, 19:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. dets 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

22. dets 2025, 19:02 UTC

Market Talk

Precious Metals Climb to New Heights -- Market Talk

22. dets 2025, 18:45 UTC

Market Talk

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22. dets 2025, 18:30 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22. dets 2025, 18:23 UTC

Omandamised, ülevõtmised, äriostud

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22. dets 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

22. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22. dets 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

101 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.